RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 3
SP 12
OP 13
DO 10.1177/155989770700700305
UL http://mdc.sagepub.com/content/7/3/12.2.abstract
AB The AVOREN trial was conducted to compare interferon alone with interferon plus bevacizumab for the treatment of metastatic renal cell carcinoma (RCC). The findings of the trial represent an important step in the recent advances in the treatment of RCC.